Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 7:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 25 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Cardiovascular Disease
Interventions
oral education & written tips for remembering medications, pill box, pocket medication card, sharing information with community pharmacist, Medication use evaluations by community pharmacist, informing physician if patient has stopped a medication, Routine discharge counseling, Letter to physician/discharge summary
Behavioral · Device · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Stage D Heart Failure
Interventions
Sacubitril-Valsartan, Usual care (standard-of-care) arm
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Peripartum Cardiomyopathy, Postpartum
Interventions
Bromocriptine, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Second Placebo
Drug
Lead sponsor
Dennis M. McNamara, MD, MS
Other
Eligibility
18 Years and older · Female only
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
64
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more
Conditions
Cognitive Decline, Blood Pressure, Hypertension
Interventions
Clinical Support Decision Tool
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
70 Years and older
Enrollment
4,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Acute Decompensated Heart Failure
Interventions
Placebo, Metolazone
Drug
Lead sponsor
Scripps Health
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
La Jolla, California
Completed Phase 3 Interventional Results available

HALT Progression of Polycystic Kidney Disease Study A

NCT00283686
Conditions
Kidney, Polycystic
Interventions
Lisinopril, Telmisartan, Placebo, Standard Blood Pressure Control, Low Blood Pressure Control
Drug · Other
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
15 Years to 64 Years
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
7
States / cities
Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more
Conditions
Acute Decompensated Heart Failure
Interventions
Change of treatment plan
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Gainesville, Florida
Conditions
Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
Interventions
CardioMEMS HF System, HeartMate 3 Left Ventricular Assist System, Guideline Medical Directed Therapy
Device · Other
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
850 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
57
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 51 more
Recruiting Phase 4 Interventional

The STOP-MED CTRCD Trial

NCT06183437
Conditions
Heart Failure, Cardiotoxicity, Cardiac Toxicity, Antineoplastics Toxicity, Cancer
Interventions
Stopping Heart Failure Medication(s)
Other
Lead sponsor
Dinesh Thavendiranathan
Other
Eligibility
18 Years and older
Enrollment
335 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
2
States / cities
Los Angeles, California • Boston, Massachusetts
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Focusing on the Menopausal Transition to Improve Mid-Life Women's Health

NCT06975111
Conditions
Menopause, Menopause Hot Flashes, Menopause Related Conditions, Cardiovascular
Interventions
Metformin, semaglutide, Anti-hypertensives, Lipid Lowering Medication, Life style intervention, Fezolinetant, Hormonal therapy
Drug · Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
45 Years to 55 Years · Female only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
3
States / cities
Aurora, Colorado • Chapel Hill, North Carolina • Richmond, Virginia
Conditions
IgA Nephropathy
Interventions
Intravenous Rituximab, ACE/ARB, Omega-3 Fatty Acid Fish Oil Supplement
Drug · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
5
States / cities
San Francisco, California • Rochester, Minnesota • New York, New York + 2 more
Conditions
Community-acquired Pneumonia, Influenza, COVID-19
Interventions
Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir
Drug · Other · Biological + 1 more
Lead sponsor
UMC Utrecht
Other
Eligibility
18 Years and older
Enrollment
20,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2028
U.S. locations
11
States / cities
Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more
Conditions
Heart Failure
Interventions
Sacubitril/valsartan, ACEI or ARB and no sacubitril/valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,614,719 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Hypertension, Metabolic Syndrome
Interventions
Aliskerin/Valsartan and Rampiril
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Active, not recruiting No phase listed Observational

Rubix LS Diabetic Kidney Disease (DKD) Registry Study

NCT07348718
Conditions
Diabetic Kidney Disease (DKD)
Interventions
Kidney-Protective Therapies Used in Routine Care
Drug
Lead sponsor
Rubix LS
Industry
Eligibility
18 Years to 70 Years
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lawrence, Massachusetts
Conditions
Acute Decompensated Heart Failure
Interventions
Experimental: Placebo, Experimental: Metolazone
Drug
Lead sponsor
Aultman Health Foundation
Other
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Canton, Ohio
Conditions
Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Carvedilol, Laboratory Biomarker Analysis, Patient Observation
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
491 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
577
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Hot Springs, Arkansas + 375 more
Conditions
Heart Failure
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Conditions
Coronary Artery Disease
Interventions
High dose potent statin, ACE-I (lisinopril) or ARB (losartan), Aspirin 81 enteric coated tablet daily, Lifestyle Counseling, Quality of Life Questionnaires
Drug · Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
2,476 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
80
States / cities
Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 54 more
Conditions
Medication Adherence
Interventions
Increasing Medication Adherence through Physician Incentives and Messaging
Other
Lead sponsor
National Bureau of Economic Research, Inc.
Other
Eligibility
65 Years and older
Enrollment
734 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Louisville, Kentucky
Withdrawn Not applicable Interventional

ACEi ARB Withdrawal in CKD Patients

NCT03957161
Conditions
Chronic Kidney Disease, Blood Pressure, Angiotensin-converting Enzyme Inhibitor, Angiotensin Receptor Blockers
Interventions
Continuation of ACEi and/or ARBs
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
San Francisco, California
Conditions
Hypertension, Hypotension
Interventions
ACEI or ARB
Drug
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
18 Years and older
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Brooklyn, New York
Not listed Not applicable Interventional

Transform CV Risk in Diabetes

NCT05948969
Conditions
Type 2 Diabetes
Interventions
Decision support, Facilitated referral to a cardiometabolic team-based center
Other
Lead sponsor
American College of Cardiology
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Washington D.C., District of Columbia